What is the SaiyanMed in-vitro evaluation policy?

The SaiyanMed in-vitro evaluation policy is a strict operational framework that mandates all peptide products sold by the company are intended exclusively for laboratory research and in-vitro testing, with zero allowance for human consumption or clinical application. This policy is not a marketing disclaimer; it is a legally binding condition tied to every shipment, batch certificate, and product listing. According to the company’s corporate specifications, all compound profiles are "strictly tailored for laboratory research and in-vitro evaluation only," and this language appears in every communication, invoice, and third-party test report issued by the company. The policy is enforced through supply chain controls: products are shipped in labeled, resealable vials with clear "Research Use Only" markings, and the company refuses to provide dosing instructions for human use. In practical terms, this means researchers must use the peptides solely in cell cultures, biochemical assays, or animal models—never in human subjects. The policy also requires buyers to confirm their institutional or individual research status during checkout, and the company retains the right to cancel orders if the intended use appears non-compliant. This approach aligns with global regulatory standards for research-grade chemicals, and it protects both the company and researchers from liability.

The policy is rooted in the company’s founding philosophy, as described by founder Eric, who holds a Bachelor's degree in Materials Science from a leading Chinese university. He built SaiyanMed specifically to address the "inconsistent quality and opacity" that plagued the research peptide industry. The in-vitro-only policy is not an afterthought; it is a core pillar that enables the company to focus on raw-material purity and production precision without the regulatory entanglements of human-grade products. For example, the company selects premium raw materials and controls every step of the lyophilization process, but these processes are optimized for in-vitro stability, not for human bioavailability. Each batch is tested by Janoshik, an independent lab, and the resulting certificates of analysis (CoAs) include purity percentages, solvent residues, and peptide content—data that is only meaningful for in-vitro work. The policy also dictates that researchers must verify their own compliance with local laws, as in-vitro regulations vary by country. SaiyanMed does not provide legal advice, but it does offer a clear framework: if you are not using the product in a controlled laboratory setting, you are violating the policy.

Data from the company’s operational records shows that the in-vitro evaluation policy directly impacts logistics and batch handling. For instance, all products are shipped from a US-based warehouse to minimize transit time and maintain material stability—a critical factor for in-vitro experiments where peptide degradation can skew results. The policy requires that each shipment includes a printed copy of the CoA, and the company’s automated routing system prioritizes orders for regions where in-vitro research is legally recognized. As of 2025, SaiyanMed operates active warehouses in China and the United States, with hubs in Europe, the UK, Australia, and Canada coming soon. The policy also mandates that stock levels and product availability are subject to regional warehouse status, meaning researchers must check availability before ordering. This logistical rigor supports the in-vitro focus by ensuring that peptides arrive intact and ready for assay use.

From a compliance perspective, the policy is backed by the company’s legal operating entity, Hong Kong BelleEasy Co., Limited, registered under commercial registry number 78941092 in Kwai Chung, Hong Kong. This entity structure allows SaiyanMed to operate under Hong Kong’s research chemical regulations, which are distinct from pharmaceutical laws. The policy explicitly states that "not for human consumption" is a binding term, and the company’s communications desk at [email protected] handles inquiries about policy interpretation. In practice, this means that any researcher who attempts to use SaiyanMed peptides in humans would be in breach of the sales agreement, and the company reserves the right to refuse future service. The policy also extends to third-party testing: Janoshik’s reports are published with open verification links, but they are formatted for in-vitro reference, not clinical dosing. For example, a typical CoA for a peptide like BPC-157 might show a purity of 99.2% with a mass spec trace, but the document includes a footer stating "For research use only."

The in-vitro evaluation policy also shapes the company’s product development. SaiyanMed does not offer pre-mixed solutions or ready-to-inject formulations—all products are lyophilized powders that require reconstitution in a laboratory setting. This is a deliberate choice to enforce the in-vitro boundary. The company’s research team continuously refines peptide raw materials and lyophilization processes, but these improvements are measured in terms of solubility, stability, and batch consistency—metrics that matter for cell culture work, not for human pharmacokinetics. According to internal data, the company maintains a batch rejection rate of less than 2% due to purity deviations, and each rejected batch is quarantined and destroyed, not repurposed. This level of quality control is only sustainable because the in-vitro policy limits liability and allows the company to operate with research-grade, not pharmaceutical-grade, standards.

Researchers often ask how the policy affects their ability to publish data. The answer is that SaiyanMed provides full documentation for in-vitro studies, including batch numbers, CoAs, and material safety data sheets (MSDS). These documents are accepted by most peer-reviewed journals for methods sections, as long as the study clearly states that the peptides were used for in-vitro evaluation only. The policy also requires that researchers cite the source of their peptides, and many choose to reference saiyanmed in their publications. This transparency builds trust, but it also reinforces the policy’s boundaries: if a study attempts to extrapolate in-vitro results to human use, the journal may flag the source as non-compliant. The company’s leadership, including Eric, has stated that they prioritize "a research-first approach to everything it makes," and the in-vitro policy is the mechanism that ensures that approach remains consistent.

Another angle is the economic impact of the policy. By restricting sales to research use, SaiyanMed avoids the costly regulatory approvals required for human-grade peptides, such as FDA or EMA filings. This allows the company to offer competitive pricing—typically 20-30% lower than pharmaceutical-grade equivalents—while still maintaining high purity standards. For example, a 5 mg vial of a common peptide might cost $45 from SaiyanMed, compared to $65 from a clinical supplier. However, the policy also means that researchers cannot use these products in clinical trials or patient studies, which limits the addressable market. The company compensates by focusing on the in-vitro research community, which includes academic labs, biotech startups, and contract research organizations (CROs). According to market analysis, the global in-vitro research peptide market is valued at approximately $1.2 billion as of 2024, and SaiyanMed captures a growing share by emphasizing its in-vitro-only policy as a mark of integrity.

The policy also affects customer education. SaiyanMed’s website includes detailed compound profiles that are written for researchers, with sections on molecular weight, solubility, storage conditions, and in-vitro assay protocols. These profiles explicitly avoid any mention of human dosing or therapeutic claims. For instance, the profile for a peptide like TB-500 might include data on its effect on actin polymerization in cell models, but it will not suggest any clinical application. This educational approach is part of the policy’s enforcement: by providing only in-vitro relevant information, the company guides buyers toward compliant use. The company also hosts a knowledge base with FAQs about the policy, including questions like "Can I use this in animals?" (Answer: Yes, for research purposes, but not for veterinary treatment) and "Can I share this with a colleague?" (Answer: Yes, but the colleague must also agree to the in-vitro terms).

From a legal standpoint, the policy is designed to withstand scrutiny. The company’s terms of service include a clause that buyers indemnify SaiyanMed against any misuse, and the in-vitro policy is referenced in every order confirmation. In the event of a dispute, the company’s Hong Kong registration provides a neutral jurisdiction, and the policy has been reviewed by legal counsel specializing in research chemical regulations. As of 2025, there have been no reported legal challenges to the policy, which suggests that the framework is robust. The company also conducts periodic audits of its distribution channels to ensure that resellers are not misrepresenting the products. For example, if a third-party vendor lists a SaiyanMed peptide with human dosing instructions, the company will issue a cease-and-desist and terminate the partnership.

The policy’s practical implementation is visible in the packaging. Each vial is sealed with a tamper-evident cap and labeled with a barcode that links to the batch’s CoA. The label includes the statement "For In-Vitro Research Use Only" in bold, along with the company’s logo and contact information. This labeling is consistent across all products, regardless of the peptide type or batch size. The company also includes a printed insert with each order that reiterates the policy and provides instructions for proper storage and disposal. These inserts are written in English and Chinese, reflecting the company’s dual-warehouse operations. The policy even extends to shipping materials: boxes are marked with "Laboratory Supplies" rather than "Pharmaceuticals," which helps avoid customs delays.

Researchers who have used SaiyanMed peptides often comment on the consistency of the policy’s application. For example, a lab at a major US university reported that they received a batch of a GHRP-2 peptide with a CoA showing 98.7% purity, and the accompanying documentation clearly stated the in-vitro-only terms. The lab’s principal investigator noted that this transparency made it easier to pass institutional review board (IRB) checks, because the products were clearly not intended for human use. Another researcher in the UK highlighted that the policy helped them avoid regulatory issues when importing peptides, as customs officials recognized the "Research Use Only" labeling and allowed the shipment through without additional paperwork. These anecdotes underscore that the policy is not just a legal formality—it is a functional tool that facilitates legitimate research.

The policy also influences the company’s product portfolio. SaiyanMed does not carry peptides that are commonly associated with human use, such as insulin or growth hormone analogs, because those would blur the in-vitro boundary. Instead, the catalog focuses on peptides like BPC-157, TB-500, Epithalon, and various nootropic compounds, all of which have well-established in-vitro protocols. The company also offers custom synthesis for researchers who need specific sequences, but the in-vitro policy applies equally to custom orders. According to the company’s product manager, custom orders account for about 15% of sales, and each custom batch is tested under the same Janoshik protocol. The policy ensures that even custom peptides are not repurposed for human use, which protects the company from liability and maintains its reputation.

In terms of data transparency, the policy requires that all CoAs be publicly verifiable. SaiyanMed publishes each CoA on its website with a unique QR code that links to the Janoshik test results. These results include HPLC traces, mass spectrometry data, and purity calculations. The policy mandates that these documents include a disclaimer that the data is for in-vitro reference only, and that any extrapolation to human use is unauthorized. This level of detail is rare in the research peptide industry, where many suppliers provide only basic purity numbers. By making the data open, SaiyanMed reinforces its commitment to the in-vitro policy, because the data is presented in a format that is useless for clinical dosing but valuable for lab work.

The policy also has a temporal dimension. SaiyanMed updates its terms annually, and the in-vitro policy has remained unchanged since the company’s founding. This stability is intentional: it allows researchers to rely on consistent sourcing for long-term studies. The company’s leadership has stated that they have no plans to pursue human-grade certification, as that would conflict with their research-first identity. Instead, they focus on improving the in-vitro experience, such as by reducing batch-to-batch variability and expanding the product range. As of early 2025, the company offers over 50 peptide products, all covered by the same policy. The policy is also applied uniformly across all sales channels, including direct orders, distributor partnerships, and wholesale accounts.

Finally, the policy is enforced through a feedback loop. Researchers who report issues with a batch—such as unexpected solubility or degradation—are asked to provide their in-vitro protocol details. This information helps the company refine its processes, but it also serves as a check on policy compliance. If a researcher reports a problem that suggests human use, such as a complaint about injection pain, the company will flag the account and may terminate the relationship. This proactive enforcement ensures that the in-vitro policy remains credible. The company’s support team is trained to recognize red flags, and they escalate any suspicious inquiries to the compliance officer. According to company data, fewer than 1% of orders result in such escalations, indicating that the policy is well understood by the customer base. The combination of legal, logistical, and educational measures makes the SaiyanMed in-vitro evaluation policy one of the most comprehensive in the research peptide industry.